Introduction: Natural killer (NK) cells are innate immune effector cells which can mediate antibody dependent cellular cytotoxicity (ADCC) and lyse cancer cells. Harnessing NK cell function against multiple myeloma (MM) is of high interest and multiple strategies are currently under development.
Exportin-1 (XPO1) is a nuclear export protein which inhibits the function of tumour suppressor proteins and facilitates oncogene mRNA translation. Selinexor is a first-in-class XPO1 inhibitor approved for the treatment of relapsed or refractory MM that induces cancer cell apoptosis. In addition, selinexor has recently been shown to promote NK cell cytotoxicity against B cell lymphoma cells. This study aimed to determine whether selinexor augments NK cell activation against MM cells both alone, and in combination with the anti-CD38 antibody daratumumab.
Methods: A panel of MM cell lines (MM.1S, U266 and RPMI-8226) were incubated with clinically relevant concentrations of selinexor for 24 hours, then either assessed for expression of ligands for NK cell receptors (KIR, NKG2A, NKG2D and NKp46), or co-cultured with primary human NK cells ± daratumumab. Following co-culture, NK-mediated lysis of MM cells was assessed by propidium iodide staining and NK cell degranulation assessed by CD107a expression.
Results: Selinexor pre-treatment of MM cells significantly increased NK cell degranulation (p<0.05) and enhanced NK specific lysis of MM targets (p<0.05). Furthermore, selinexor pre-treatment significantly (p<0.05) enhanced NK cell activation in combination with daratumumab compared to daratumumab alone. Importantly, selinexor did not alter surface expression of CD38 on MM cell lines. To investigate the mechanism behind this enhanced NK cell function, we assessed the effect of selinexor on the expression of NK cell ligands by MM cells. Selinexor increased the expression of ULBP1/2/5/6 (2-fold, p<0.001) which bind to the NK cell activating receptor NKG2D. In addition, selinexor decreased MM cell expression of HLA-E (30% decrease, p<0.05) which binds to the inhibitory NK receptor NKG2A.
Conclusions: These data suggest that selinexor may promote the efficacy of NK targeted therapeutics in multiple myeloma.
Disclosures
Forconi:Astra-Zeneca: Honoraria, Speakers Bureau; beigene: Honoraria, Other: Travel and accommodation, Speakers Bureau; Janssen-cilag: Honoraria, Other: Travel and accommodation, Speakers Bureau; Abbvie: Honoraria, Other: Travel and accommodation, Speakers Bureau. Cragg:GSK: Research Funding; iTeos: Research Funding; Gilead: Research Funding; GLG: Other: Educational and advisory role; Merch KGaA: Other: Educational and advisory role; Baxalta: Other: Educational and advisory role; Boehringer Ingelheim: Other: Educational and advisory role; Roche: Other: Educational and advisory role, Research Funding; BioInvent International: Consultancy, Research Funding; UCB: Research Funding. Walker:Karyopharm: Current Employment. Blunt:Karyopharm: Research Funding.
